Clinical trials: Urinary Bladder Disease
Overactive Bladder (OAB)
Comparing Treatments for Overactive Bladder in Taiwan: A Study of Outcomes
Overactive bladder (OAB) syndrome is a prevalent condition that significantly impairs patients' quality of life. Standard therapeutic strategies include oral antimuscarinics (e.g., solifenacin), beta-3 adrenergic agonists (e.g.…
- Trial name
- NCT07025642
- Testing
- Urodynamic evaluation before and after solifenacin treatment., Urodynamic evaluation before and after mirabegron treatment., Urodynamic evaluation before and after combined treatment with solifenacin and mirabegron.
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Mackay Medical College
Bladder Tumors, Bladder Tumor
Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial
This phase I study evaluates intravesical calcium electroporation (CaEP) with a new transurethral electrode. The study is primarily designed to assess the safety of CaEP and secondarily, to preliminary explore the efficacy in…
- Conditions
- Bladder Tumors, Bladder Tumor, Urothelial Carcinoma (UC), Urothelial Carcinoma Bladder
- Trial name
- CALCIFER (NCT07555769)
- Testing
- Calcium electroporation, Intratumoral calcium injection, Transurethral electroporation
- Volunteers
- 20 people
- Sponsor
- Juan Luis Vásquez
Overactive Bladder, Benign Prostatic Hyperplasia
Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.
The purpose of this study is to investigate the safety and efficacy of combination therapy involving β3-adrenoceptor agonist, mirabegron, and α-blockers for the treatment of OAB symptoms in male patients with BPH.
- Trial name
- NCT02279615
- Testing
- Mirabegron, Tamsulosin
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Bladder (Urothelial, Transitional Cell) Cancer, Non Muscle Invasive Bladder Cancer
Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?
Patients with extensive transurethrally unresectable very-high-risk non-muscle-invasive bladder cancer (NMIBC) may achieve a tumor-free status after systemic immunotherapy-based bladder-sparing treatment combined with…
- Trial name
- NCT07625527
- Testing
- Active Surveillance, PD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy
- Where
- 4 sites in China
- Volunteers
- 120 people
- Sponsor
- Tianjin Medical University Second Hospital
Bladder Cancer
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
The purpose of this study is to determine whether Patients with Locally Advanced or Metastatic Bladder Cancer who receive Eribulin Mesylate Administered in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus…
- Trial name
- NCT01126749
- Testing
- Gemcitabine, E7389, Cisplatin
- Where
- 42 sites in United States, Germany and 4 more
- Volunteers
- 92 people
- Sponsor
- Eisai Inc.
High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
This phase I trial tests the safety and side effects of a PD-L1/IDO peptide vaccine (IO102-IO103) in combination with pembrolizumab in treating patients with non-muscle invasive bladder cancer.
- Conditions
- High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Trial name
- NCT05843448
- Testing
- PD-L1/IDO Peptide Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, Davis
Bladder Cancer
Markers of Response to Intravesical Bladder Cancer Therapy
The goal of this laboratory research study is to see if researchers can predict whose cancer will stay in remission and whose will return in patients receiving treatment for bladder cancer.
- Trial name
- NCT01007058
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Overactive Bladder
Changes in the Urinary Microbiome and Metabolome During Treatment of the Overactive Bladder in Female Patients
This is a non-interventional study that will not pose any burden for the participants. The study subjects will be examined and treated in a standard manner according to current clinical recommendations for the treatment of…
- Trial name
- NCT06921746
- Testing
- Urine Microbiological and Metabolomic Analysis
- Where
- 4 sites in Czechia
- Volunteers
- 80 people
- Sponsor
- University Hospital Ostrava
Overactive Bladder
Overactive Bladder (OAB) Voiding Diary and Urodynamics Correlation Study
This is a prospective cohort study study with the primary aim of identifying the strongest correlating parameters between voiding diaries and UDS studies most predictive for each type of urologic condition.
- Trial name
- NCT03473782
- Testing
- Voiding Diary, Urodynamics Correlation Study
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- NYU Langone Health
Overactive Bladder, Urge Incontinence
AURA-2: Augmenting Urinary Reflex Activity
AMBER AURA-2 study (Augmenting Urinary Reflex Activity 2) is a short-duration (6 month) safety and electrophysiological study using an implanted Amber UI system and two electrode leads to provide closed-loop pudendal nerve…
- Trial name
- AURA-2 (NCT05241379)
- Testing
- Amber UI System
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- Amber Therapeutics Ltd
Interstitial Cystitis, Bladder Pain Syndrome, Quality of Life
Quality of Life Analysis in Bladder Pain Syndrome/Interstitial Cystitis
The aim of our study was to evaluate whether there is a higher prevalence of anxiety-depressive disorders in women with interstitial cystitis than in women with chronic non-neoplastic pain with or without fibromyalgia, to examine…
- Trial name
- BPS/IC (NCT05630742)
- Testing
- chronic non-neoplastic pain
- Where
- Italy
- Volunteers
- 69 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Bladder Cancer, Laparoscopy
Trial of Open Versus Laparoscopic Radical Cystectomy at a Laparoscopic Naive Center
This study is a prospective randomised controlled study of urinary bladder cancer patients presented to urology unit at National Cancer Institute; Cairo University.
- Trial name
- NCT04838873
- Testing
- Open radical cystectomy, Laparoscopic-assisted radical cystectomy
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Bladder Cancer
Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006118
- Testing
- cisplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 12 sites in France, Monaco
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Bladder Urothelial Carcinoma, Bladder Cancer
Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer
This is a multicenter, prospective, open-label, Phase II, four-arm parallel study evaluating the efficacy and safety of different sensitization strategies combined with disitamab vedotin and toripalimab in patients with…
- Trial name
- SYSTEM (NCT07717242)
- Testing
- Disitamab vedotin, Toripalimab, Sitagliptin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Carcinoma in Situ of Bladder, Bladder Cancer
Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder
The purpose of this study is to test if an experimental drug called Durvalumab (Medi4736) given by intravenous (IV) infusion is effective in treating carcinoma in situ (CIS) of the bladder that no longer responds to Bacillus…
- Trial name
- NCT02901548
- Testing
- Durvalumab, Cystoscopy with Biopsy
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Overactive Bladder Syndrome, Detrusor Overactivity
Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker
About one to two million women in Taiwan suffers from overactive bladder (OAB). The most commonly used anti-muscarinic drugs have a high rate of side effects.
- Trial name
- NCT04693897
- Testing
- Mirabegron 50 MG, Solifenacin Succinate 5 MG
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Female Sexual Dysfunction, Overactive Bladder
Sexual Function Trial of Overactive Bladder: Medication Versus PTNS
Sexual dysfunction affects approximately 45% of women with an even greater incidence reported in women with overactive bladder symptoms, despite this there is a lack of FDA approved treatments for sexual dysfunction in this…
- Trial name
- STOMP (NCT03500146)
- Testing
- Anticholinergic, PTNS
- Where
- 5 sites in United States
- Volunteers
- 175 people
- Sponsor
- Medstar Health Research Institute
IC, Hunner Type Interstitial Cystitis
The Study is Being Conducted to Find a New Treatment for Patients Suffering From Interstitial Cystitis With Hunner's Lesions
To evaluate the efficacy and safety of Neovasculgen in interstitial cystitis with Hunner's lesions to reduce cicatricial changes in the bladder caused by electrocoagulation and to prevent secondary bladder shrinkage with a…
- Conditions
- IC, Hunner Type Interstitial Cystitis, Bladder Pain Syndrome
- Trial name
- NCT07459790
- Testing
- Neovasculgen®
- Where
- Russia
- Volunteers
- 180 people
- Sponsor
- JSC NextGen
Pelvic Organ Prolapse, Uterine Prolapse
Efficacy Study of Vaginal Mesh for Prolapse
The primary aim of this double-blind, randomized clinical trial (RCT) is to test the hypothesis that the addition of a standardized technique of interpositional synthetic polypropylene mesh placement improves the one-year outcome…
- Conditions
- Pelvic Organ Prolapse, Uterine Prolapse, Vaginal Prolapse, Cystocele
- Trial name
- VAMP (NCT00475540)
- Testing
- synthetic monofilament polypropylene mesh
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Medstar Health Research Institute
Detrusor Underactivity
Detrusor Underactivity: Presentation and Urodynamic Characteristics
Detrusor underactivity (DU) is a known disease of the muscles of the urinary bladder that defined as a weak contraction of the muscle resulting in a failure to achieve complete bladder emptying.
- Trial name
- NCT04336280
- Testing
- Symptom questionnaire, Urodynamics
- Where
- Jordan
- Volunteers
- 206 people
- Sponsor
- Mutah University